- Conditions
- Hemophilia A, Factor VIII (FVIII)
- Interventions
- Half-life factor VIII based replacement therapy, Non-FVIII based replacement therapy
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 6 Months and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2033
- U.S. locations
- 1
- States / cities
- Dallas, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–3
of 3
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Hemophilia A, Hemophilia B
- Interventions
- rFVIIIFc, rFIXFc, non-Fc FVIII replacement products, non-Fc FIX replacement products
- Biological · Drug
- Lead sponsor
- Bioverativ Therapeutics Inc.
- Industry
- Eligibility
- Male only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 2
- States / cities
- Los Angeles, California • East Lansing, Michigan
- Conditions
- Hemophilia A, Factor VIII
- Interventions
- Eloctate, Adynovate, Emicizumab
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- Up to 17 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas